Exploring possible connections between vitamins D & B, inflammation and psychiatric disorders in elderly psychiatric in-patients
| ISRCTN | ISRCTN71047363 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN71047363 |
| Secondary identifying numbers | PFP1298-16 |
- Submission date
- 20/11/2017
- Registration date
- 12/12/2017
- Last edited
- 01/10/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Mental and Behavioural Disorders
Plain English summary of protocol
Background and study aims
Research has demonstrated that inflammation (swelling) is an integral part of several psychiatric disorders. Cytokines are molecules that regulate inflammation and can be used as inflammatory markers in peripheral blood (components of blood). Vitamin D and B have also been shown to be associated with both psychiatric disorders and inflammation, but the potential connection between these vitamins, inflammation and psychiatric disorders is still to be explored. Most studies have been conducted on younger adults and there are only a few studies on inflammation, vitamins and psychiatric disorders in elderlyThe aim of this study is to investigate possible association between vitamin D/B and inflammatory markers (cytokines) in elderly psychiatric patients.
Who can participate?
Patients aged 60 and older who are admitted to a psychiatric ward in Tromsø, Norway.
What does the study involve?
At admission and discharge, blood samples are collected from all patients. In addition to a standard analysis of the blood (checking number of red and white blood cells, liver and kidney function tests, electrolytes etc.), the blood is screened for molecules that signal inflammation. Presence of these molecules, called cytokines, indicates that there is an ongoing inflammation in the body and/or the brain, a phenomenon that have been demonstrated in various psychiatric disorders. Levels of vitamin D, various forms of vitamin B and sink, are also measured in the blood. The samples are assessed to see if there is any connection between lower levels of the vitamins and sink, and cytokines, as well as all these factors and psychiatric diagnosis and life style factors (smoking, alcohol, eating habits etc).
What are the possible benefits and risks of participating?
The patients in this study will receive assessment and treatment as usual, i.e. they will undergo standard procedures/treatment during their admission. Hence, being a part of the study does not entail an increased risk of complications, nor any directs benefits, compared to treatment as usual.
Where is the study run from?
University Hospital of Northern Norway (Norway)
When is the study starting and how long is it expected to run for?
March 2008 to July 2019
Who is funding the study?
Helse Nord RHF (Norway)
Who is the main contact?
Dr Erlend Bugge
Contact information
Scientific
University Hospital of North Norway
Tromsø
9038
Norway
 ORCID ID |
0000-0003-2388-4251 |
|---|
Study information
| Study design | Observational study |
|---|---|
| Primary study design | Observational |
| Secondary study design | Cross sectional study |
| Study setting(s) | Hospital |
| Study type | Other |
| Participant information sheet | Not available in web format. Please use the contact details to request the patient information sheet. |
| Scientific title | Vitamin D, vitamin B (B1,B6,B9,B12) og cytokiner hos pasienter innlagt ved Alderspsykiatrisk avdeling, UNN Tromsø/Vitamin D, vitamin B (B1,B6,B9,B12) and cytokines in gerontopsychiatric patients admitted to a psychiatric hospital |
| Study objectives | The aim of this study is to investigate possible association between vitamin D/B and inflammatory markers (cytokines) in gerontopsychiatric in-patients. |
| Ethics approval(s) | Regional Committee for Medical and Health Research Ethics of Northern Norway, 05/02/2010 (amendment approved 02/02/2017), ref: REC North, reg. nr. 2009/1388) |
| Health condition(s) or problem(s) studied | Various psychiatric conditions |
| Intervention | This is an observational study. Participating patients are assessed, diagnosed and treated according to standard procedure (“treatment as usual”). This includes psychometrics such as the MINI International Neuropsychiatric Interview, the Montgomery and Aasberg Depression Rating Scale, the Cornell Scale for Depression in Dementia, the Mini-Mental State Examination and the Clockdrawing Test. These psychometric tools, in combination with clinical interviews and reviews of medical records, are used by experienced clinicians in psychiatric assessment and diagnosis (according to ICD-10 research criteria). Furthermore, clinical somatic assessment, as well as array of blood samples (including cytokines), are undertaken for all patients. Other diagnostic/investigative procedures are carried out when deemed necessary (X-ray, CT, MRI, EEG, ECG etc.). Based on diagnosis/assessment, patients are treated with psychotherapy, family based therapy, psychoeducation and biological treatment (notably psychopharmacological treatment), or a combination thereof, or other treatments warranted. The median length of stay is 34 days (length of stay = observational period = duration of follow up). At discharge, self reported clinical status was categorized in 5 categories: Complete recovery, Almost complete recovery, Partial recovery, No recovery and Worsening. |
| Intervention type | Other |
| Primary outcome measure | Levels of 27 cytokines in peripheral blood are measured using multiplex technology with a predefined kit (Bio-Plex Human Cytokine 27-Plex Panel) at admittance (IN) and discharge (OUT). |
| Secondary outcome measures | Levels of vitamin D, B1, B6, B9, B12 and sink in peripheral blood are measured using liquid chromatography–mass spectrometry and immunoassay methodology within the first week of admission. |
| Overall study start date | 01/03/2008 |
| Completion date | 01/07/2019 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Senior |
| Sex | Both |
| Target number of participants | 100 |
| Key inclusion criteria | 1. Patients consecutively admitted to a gerontopsychiatric ward (wide inclusion) 2, Aged 60 and older |
| Key exclusion criteria | 1. Inability to communicate and cooperate, e.g. due to a severe psychiatric condition like severe dementia or confusion/delirium 2. Medical condition likely to significantly affect the blood/plasma analysis like severe dehydration or ongoing infection. |
| Date of first enrolment | 18/03/2010 |
| Date of final enrolment | 09/12/2011 |
Locations
Countries of recruitment
- Norway
Study participating centre
9037
Norway
Sponsor information
University/education
Hansine Hansens veg 18
Tromsø
9019
Norway
"ROR" |
https://ror.org/00wge5k78 |
|---|
Funders
Funder type
Government
Government organisation / Local government
- Alternative name(s)
- Northern Norway Regional Health Authority
- Location
- Norway
Results and Publications
| Intention to publish date | 01/06/2019 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Results from the study will be published in high-impact peer reviewed journals in 2018 and 2019. |
| IPD sharing plan | Study protocol and participant level data will be available upon request. Please contact: Erlend Bugge, MD erlend.bugge@unn.no University Hospital of North Norway 9038 Tromsø Norway Ole Grønli, MD, PhD ole.k.grønli@unn.no University Hospital of North Norway 9038 Tromsø Norway |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 27/09/2018 | Yes | No |
Editorial Notes
01/10/2018: Publication reference added.
05/01/2018: Internal review.
